Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2013 | 1 |
2014 | 2 |
2018 | 1 |
2019 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.
EJHaem. 2022 Dec 12;4(1):153-164. doi: 10.1002/jha2.600. eCollection 2023 Feb.
EJHaem. 2022.
PMID: 36819180
Free PMC article.
Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression.
Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L, Aisimitula A, Nie Y, Huang Q.
Li Y, et al. Among authors: yimamu m.
Int J Hematol. 2014 Jan;99(1):79-86. doi: 10.1007/s12185-013-1472-z. Epub 2013 Nov 21.
Int J Hematol. 2014.
PMID: 24258714
Item in Clipboard
An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function.
Maimaitili Y, Inase A, Miyata Y, Kitao A, Mizutani Y, Kakiuchi S, Shimono Y, Saito Y, Sonoki T, Minami H, Matsuoka H.
Maimaitili Y, et al.
Leuk Res. 2018 Nov;74:68-74. doi: 10.1016/j.leukres.2018.09.017. Epub 2018 Oct 2.
Leuk Res. 2018.
PMID: 30300823
Item in Clipboard
An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
Mizutani Y, Inase A, Maimaitili Y, Miyata Y, Kitao A, Matsumoto H, Kawaguchi K, Higashime A, Goto H, Kurata K, Yakushijin K, Minami H, Matsuoka H.
Mizutani Y, et al. Among authors: maimaitili y.
Int J Hematol. 2019 Oct;110(4):490-499. doi: 10.1007/s12185-019-02701-2. Epub 2019 Jul 8.
Int J Hematol. 2019.
PMID: 31286402
Item in Clipboard
[Detection of p53 gene deletion in Xinjiang patients with chronic lymphocytic leukemia by fluorescence in situ hybridization and its clinical significance].
Maimaitili Y, Guzailinuer W, Wang X, Liu H, Li Y, Xiao M.
Maimaitili Y, et al.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014 Aug;31(4):499-503. doi: 10.3760/cma.j.issn.1003-9406.2014.04.020.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014.
PMID: 25119920
Chinese.
Item in Clipboard
[Detection and clinical significance of JAK2 V617F mutation in Chinese and Uyghur patients with chronic myeloproliferative in Xinjiang].
Zhang XY, Maimaitili Y, Li Y, An L, Mao M, Fu L, Baier M, Wang XM.
Zhang XY, et al. Among authors: maimaitili y.
Zhonghua Xue Ye Xue Za Zhi. 2012 Dec;33(12):1020-3.
Zhonghua Xue Ye Xue Za Zhi. 2012.
PMID: 23363794
Chinese.
Item in Clipboard
Cite
Cite